Valeant must up Allergan bid to $180-$200, J.P. Morgan survey says


Shares of Valeant Pharmaceuticals (VRX +2%) are up nicely as it prepares to raise its offer for Allergan (AGN +1.6%) by next Wednesday; a new J.P. Morgan survey of buyside investors says VRX's bid needs to hit the range of $180-$200/share.

Some 60% of respondents in the survey indicated VRX would need to offer in the range; about two-thirds of those surveyed believed an offer ultimately will prove successful.

"We feel confident that VRX can structure such a deal (using a larger cash component, CVR, collar, etc.) which would still be highly accretive," JPM says.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs